Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8450287 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(4 years from now) | |
US8101582 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Dec, 2027
(4 years from now) | |
US7795316 | EYEVANCE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Aug, 2028
(5 years from now) |
Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993471 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
US8829005 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
US9750684 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(7 years from now) | |
US8829005
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(7 years from now) | |
US9254286 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(9 years from now) | |
US9254286
(Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(9 years from now) |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic